logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences has potential drug to treat coronavirus patients with severe lung damage

Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) Gabriele Cerrone chats to Proactive London's Andrew Scott following the news they're looking to expedite development of a drug it believes could help coronavirus patients with severe lung damage.

The company’s TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor and recent testing has revealed they have a significant role to play in treating coronavirus patients.

Quick facts: Tiziana Life Sciences PLC

Price: 111.5 GBX

AIM:TILS
Market: AIM
Market Cap: £179.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 on back foot, car production stalls

Headlines from the Proactive UK newsroom. The FTSE 100 is on the back foot as the ongoing spat between the US and China pre-occupies investors. The blue-chip index shed 61 points to 6,157. Britain’s car industry produced just 197 cars in April, according to the last trade figures. That was...

3 days, 13 hours ago

2 min read